Stop RSV

What is RSV?

Respiratory syncytial virus (RSV) can infect the lungs and breathing passages, as well as the mouth, nose and throat. In adults, RSV usually manifests itself as a cold, but it can cause severe lung disease in infants. Premature infants, children under age two with chronic lung or heart conditions, and children with weakened immune systems are most at risk for developing a severe disease from RSV.

Synagis — Protecting High Risk Infants from RSV

Researchers have not yet developed a vaccine for RSV, but parents can reduce their infant's risk of RSV with Synagis. Synagis is an FDA-approved prescription injection of antibodies given monthly to help protect high-risk infants from severe RSV disease. Refer a Patient for Synagis.

How Syngais helps those most at risk

Premature babies born at 35 weeks or less

Preemies are often born before their lungs and airways are fully developed, and before they have received enough antibodies from their mothers to fight RSV. Synagis provides the antibodies the babies with under-developed lungs need to fight RSV.

Children 24 months or less with bronchopulmonary dysplasia (BPD) and/or hemodynamically significant congenital heart disease (CHD)

Certain types of heart and chronic lung disease are especially vulnerable to RSV, as well. Added antibodies from Synagis help to prevent severe RSV in these babies.

West Tennessee Healthcare (WTH) does not exclude, deny benefits to, or otherwise discriminate against any person on the grounds of race, color, national origin, age, religion, disability, Limited English Proficiency or sex, including discrimination based on gender identity, sexual orientation, sex stereotyping or pregnancy in admission to, participation in, or receipt of the services and benefits under any of its programs and activities, whether carried out by WTH directly or through a contractor or any other entity with which WTH arranges to carry out its programs and activities.

For further information about this policy, contact Amy Garner (731) 541-9914.